1
Barbara A Fries Hastings: Treatment of macular degeneration. Somerset Pharmaceuticals, Mathews Woodbridge & Collins, September 7, 1993: US05242950 (35 worldwide citation)

A method of treating macular degeneration is disclosed which comprises administering to a patient suffering from the disease a therapeutically effective amount of L-deprenyl or a pharmaceutically acceptable acid addition salt thereof for a period of time sufficient to ameliorate the disease.


2
Anthony R DiSanto: Sublingual and buccal administration of selegiline for treating certain selegiline-responsive diseases and conditions. Somerset Pharmaceuticals, Michael A Vinson & Elkins L Sanzo, September 12, 2000: US06117912 (12 worldwide citation)

The present invention is directed to improved methods for treating certain selegiline-responsive diseases or conditions and, more specifically, to methods in which selegiline is administered buccally or sublingually. Selegiline may be used ether as a free base or as a pharmaceutically acceptable aci ...


3
Anthony R DiSanto, Cheryl D Blume: Methods and pharmaceutical compositions employing desmethylselegiline. Somerset Pharmaceuticals, Vinson & Elkins, October 9, 2001: US06299901 (6 worldwide citation)

The application is directed to the treatment of one or more symptoms associated with drug withdrawal by administering desmethylselegiline.


4
Cheryl D Blume, Anthony R DiSanto: R(-)desmethylselegiline and its use in transdermal delivery compositions. Somerset Pharmaceuticals, Vinson & Elkins L, July 16, 2002: US06419948 (6 worldwide citation)

Methods and pharmaceutical compositions for using desmethylselegiline. In particular, the present invention provides novel compositions and methods for using desmethylselegiline for selegiline-responsive diseases and conditions. Diseases and conditions responsive to selegiline include those produced ...


5
Cheryl D Blume, Anthony R DiSanto: Methods employing R(−)-desmethylselegiline. Somerset Pharmaceuticals, Vinson & Elkins L, May 13, 2003: US06562365 (5 worldwide citation)

Methods and pharmaceutical compositions for using desmethylselegiline. In particular, the present invention provides novel compositions and methods for using desmethylselegiline for selegiline-responsive diseases and conditions. Diseases and conditions responsive to selegiline include those produced ...


6
Mark G Resnick: Methods for treating photodamaged skin by administering selegiline or desmethylselegiline. Somerset Pharmaceuticals, Vinson & Elkins L, March 23, 2004: US06709664 (4 worldwide citation)

The present invention is directed to methods that can be used in the treatment of wounds, burns, and photodamaged skin. Methods can be used for both humans and animals and involve the administration of compositions containing selegiline and/or desmethylselegiline.


7
Anthony R DiSanto, Cheryl D Blume: Desmethylselegiline enantiomers and their use to treat drug withdrawal symptoms. Somerset Pharmaceuticals, Vinson & Elkins L, May 13, 2003: US06562364 (4 worldwide citation)

The application is directed to the treatment of one or more symptoms associated with drug withdrawal by administering desmethylselegiline.


8
Anthony R DiSanto: S(+) desmethylselegiline and drug withdrawal. Somerset Pharmaceuticals, Vinson & Elkins L, July 16, 2002: US06420433 (4 worldwide citation)

The present invention provides novel compositions and methods for using the S-(+) enantiomer of desmethylselegiline (N-methyl-N-(prop-2-ynyl)-2-aminophenylpropane), for the treatment of selegiline-responsive diseases and conditions. Diseases and conditions responsive to selegiline include those ...


9
Cheryl D Blume, Anthony R DiSanto: Methods for treating multiple sclerosis employing desmethylselegiline. Somerset Pharmaceuticals, Vinson & Elkins L, March 2, 2004: US06699495 (4 worldwide citation)

Methods and pharmaceutical compositions for using desmethylselegiline. In particular, the present invention provides novel compositions and methods for using desmethylselegiline for selegiline-responsive diseases and conditions. Diseases and conditions responsive to selegiline include those produced ...


10
George Bobotas: Method for preventing and treating peripheral neurophathy by administering selegiline. Somerset Pharmaceuticals, Vinson & Elkins, May 29, 2001: US06239181 (4 worldwide citation)

The present invention is directed to methods for alleviating the symptoms associated with peripheral neuropathy. The neuropathy may be the result of a genetically inherited condition, systemic disease or exposure to a toxic agent. A reduction or elimination of symptoms is obtained by administering t ...